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Abstract
Background: Homozygosity (D32/D32) for the 32 bp deletion in the chemokine receptor 5 (CCR5) gene is associated with
strong resistance against HIV infection. Heterozygosity is associated with protection of HIV-1 disease progression.
Methodology/Principal Findings: We genotyped a population of 737 HIV-positive adults and 463 healthy controls for the
CCR5D32 deletion and found heterozygous frequencies of 16.2% (HIV-negative) and 17.5% (HIV-positive) among Caucasian
individuals. Analysis of CCR5D32 influence on disease progression showed notably lower viral setpoints and a longer time to
a CD4 count of ,200 ml
21 in seroconverters heterozygous for the deletion. Furthermore, we identified one HIV-positive man
homozygous for the D32 deletion.
Conclusions/Significance: The protective effect of CCR5 D32 heterozygosity is confimed in a large cohort of German
seroconverters. The HIV-infected CCR5 D32 homozygous individual, however, displays extremely rapid disease progression.
This is the 12th case of HIV-infection in this genotype described worldwide.
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Introduction
Chemokine receptor-5 (CCR5) is of major importance for the
transmission of HIV-1 (reviewed in [1,2]). CCR5D32 is a deletion
resulting in a defective phenotype of this receptor, and the first
host polymorphism with an effect on HIV-1 disease demonstrated:
CCR5D32 homozygous individuals are potently protected against
HIV-1 infection [3–6]. CCR5D32 heterozygosity has been shown
to be significantly associated with slower HIV-1 disease progres-
sion in several study cohorts [3,7–11]. Whereas other human
mutations have been demonstrated since then to also affect the
HIV disease progression rate [12–15], CCR5D32 is still regarded
as the strongest genetic factor of HIV resistance of the host known
to date [2,16]. HIV-1 infection in CCR5D32 homozygotes is
exceedingly rare, with a total of eleven cases reported worldwide
so far [17–26].
The objective of this study was to assess the influence of the
CCR5D32 deletion on susceptibility to, and progression of HIV
infection in a large German study population. A study group of
737 well characterized HIV-positive patients, including 499
seroconverters, and 463 HIV-negative controls, was examined
for presence of the deletion allele. Our results confirm the
previously conveyed CCR5D32 associations. Furthermore, we
here report one HIV-infected male displaying homozygosity for
the mutation. This individual represents the 12th HIV case with
the homozygous mutant (D32/D32) genotype known in the world.
Results
Distribution of CCR5D32 genotypes in the study cohort
and identification of an HIV-1 infected individual
homozygous for the CCR5D32 deletion
In order to examine the association of the CCR5D32 deletion
with HIV-1 susceptibility in a German study cohort for the first
time, its presence was assessed in a total of 737 seropositive
patients and 463 seronegative controls. Among the African study
participants, the D32 variant was detected in only one control
subject, who was heterozygous. In a total of 1139 Caucasians,
16.7% were CCR5D32 heterozygous (+/D32) and 0.2% were
homozygous (D32/D32), and genotypes were distributed similarly
between cases and controls: Among the seropositive study subjects,
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+/+ genotype, whereas 16.2%
were heterozygous for the deletion allele (+/D32). Of the
seronegative controls, the CCR5
+/+ genotype was found in
82.2%, while 17.5% were heterozygous. No significant association
of CCR5D32 state with serostatus was found, regardless of
whether analysis was performed by genotype frequencies (Table 1)
or by allele frequencies (data not shown).
Of particular note, one (0.1%) HIV-1 infected individual was
found to be homozygous for the CCR5D32 allele. The D32/D32
genotype is generally regarded to render almost complete
resistance against HIV-infection.
Association of CCR5D32 genotype with HIV-1 disease
progression in Caucasian seroconverters
To evaluate the impact of CCR5D32 on the progression of
HIV-1 disease in the study cohort, the strength of the association
between heterozygosity and viral load setpoints was assessed. This
revealed a trend towards decreased setpoints in heterozygous
seroconverters as compared to those with the common CCR5
+/+
genotype without reaching statistical signifcance, however (p=0.1;
Fig. 1). A protective effect of CCR5D32 heterozygosity became
also apparent in Kaplan-Meier analysis of 496 therapy-naı ¨ve
seroconverters demonstrating that mutation carriers reached the
study endpoint of ,200 ml-1 CD4
+ T-cells later than carriers of
the common gene variant (p=0.1; Fig. 2).
Characteristics of an HIV-1 positive individual
homozygous for the CCR5D32 deletion
The HIV-1 patient tested D32/ D32 homozygous (termed
patient #12 hereafter) is a German male in his early 40s whose
only risk factor for HIV-1 infection is homosexual contact. Results
of HIV-1 antibody / antigene tests were repeatedly negative until
mid-February, 2002. In June 2002, this patient presented with
weakness, a sore throat, pronounced cervical, inguinal and axillary
lymphadenopathy, a truncal erythematous macular rash as well as
leukopenia (nadir, 2.700 ml
21 ) and thrombocytopenia (79 ml
21). A
suspect diagnosis of acute retroviral syndrome was corroborated
by a positive enzyme immunoassay. Western Blot was initially
negative for all bands, but turned positive for the p24 and GP160
bands on the patient’s follow-up visit one week later. At this visit,
his CD4
+ T-cell count was 344 ml
21, his CD8
+ T-cell count was
826 ml
21 and the viral RNA load in his plasma had a
concentration of 2.323.000 copies ml
21. Highly active antiretro-
viral therapy (HAART) with efavirenz, stavudine and lopinavir-
ritonavir was initiated 8 days after the first positive test result. Full
suppression of viremia and a CD4
+ T-cell count rise were observed
until eight months after infection (Fig. 3), when treatment was
suspended following the request of the patient. Clinically, apart
from one episode of Chlamydia-associated proctitis successfully
treated with azithromycine, this patient was doing well subsequent
to HAART discontinuation. However, in the following months
disease progression parameters deteriorated rapidly. Within the
course of ten months CD4
+ T-cells count dropped from 924 ml
21
(28.1%) to 275 ml
21 (12.9%), while plasma viral load rose from
below the detection limit of 50 copies ml
21 to 22 400 copies ml
21.
This prompted re-initiation of antiretroviral therapy with
zidovudine plus lamivudine and efavirenz; viral load became
undetectable and CD4
+ T-cell counts recovered. A CD4 decline to
164 ml
21, seen when the patient suffered from Shigella sonnei
gastroenteritis, was transient. As of now, patient #12 has
remained on the same therapeutic regime for over four years,
with stable CD4
+ T-cell percentages ranging between 20 and 26%
ml
21 and viral loads below the limit of detection.
Discussion
Distribution of CCR5D32 genotypes among seropositive
and seronegative study participants
Variations within the host’s genome contribute substantially to
the individual course of HIV-1 infection. Our results obtained
from the examination of a large study collective confirm the
previous findings of a high prevalence of the CCR5D32 allele in
European Caucasians [21,38,39]; it may therefore significantly
affect susceptibility to HIV-infection, as well as progression to
AIDS in this population.
Some studies have proposed that CCR5D32 heterozygotes
could be protected against HIV transmission [6,40,41]. The
seronegative controls examined here are not exposed but
uninfected individuals in the strict sense. However, assuming that
the resistance conferred by the +/D32 genotype was strong, our
study would have revealed an under-representation of this
genotype in HIV-infected as compared to uninfected subjects.
As CCR5+/D32 frequencies were similar in both groups, our
Table 1. CCR5D32 genotype distribution in HIV-positive and
HIV-negative study subjects
HIV-positive HIV-negative
number ( % ) P-value
1
Caucasian
+ / + 595 (83.7) 352 (82.2)
+ / D32 115 (16.2) 75(17.5) 0.78
D32 / D32 1 (0.1) 1 (0.2)
African
+ / + 35 (100.0) 25 (96.2)
+ / D32 0 1 (3.8) 0.24
D32 / D32 0 0
1262o r3 62 x2 comparisons, depending on the presence or absence of
heterozygous and mutant homozygotes in the respective subgroup.
Comparisons were conducted separately according to ethnicity
doi:10.1371/journal.pone.0002747.t001
Figure 1. Relation of CCR5D32 genotype with viral setpoints in
319 Caucasian seroconverters. Scattered dots represent individual
viral setpoints (see Material and Methods for a definition), whereas
vertical lines demarcate the median in each genetic group.
doi:10.1371/journal.pone.0002747.g001
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investigators, indicating that heterozygosity-associated protection
is mild [1,7].
Association of CCR5D32 carriage with HIV-1 disease
progression in Caucasian seroconverters
The well-established CCR5+/D32 related restriction against
disease progression was also reflected in this survey. Seroconver-
ters displaying the normal gene variant were compared with
seroconverters displaying the deletion. The CCR5+/D32 genotype
was related to lower setpoint viral loads, as well as slower
progression to the study endpoint of 200 CD4
+ cells
2ml in the
Kaplan-Meier analysis [7–11,41].
Identification of an HIV-1 positive individual homozygous
for the CCR5D32 deletion
So far, only 11 CCR5D32 homozygous HIV-1 infected
individuals with the CCR5 D32/D32 genotype have been
identified amongst a total of more than 20,000 HIV-positive
individuals enrolled in several globally distributed cohorts. We
Figure 2. Kaplan Meier Analysis of 506 seroconverters showing a relation of CCR5D32 genotype with a CD4
+ T-cell count ,200 ml
21.
A CD4
+ T-cell count ,200 ml-1 was documented for n=57 of 422 individuals homozygous for the wildtype CCR5 genotype, and for n=9 out of 84
CCR5D32 heterozygotes. Data censoring was due to introduction of antiretroviral therapy before a CD4 cell count of 200 ml
21 was reached. The
difference between both groups implied by the Kaplan-Meier diagram is reflected in a statistical trend (p=0.1 as calculated by the Log-Rank test).
doi:10.1371/journal.pone.0002747.g002
Figure 3. Clinical, immunological and viral load characteristics in an HIV-infected patient homozygous for the CCR5D32 deletion
(patient#12). Antiretroviral therapy was initiated twice, eight days after diagnosis with efavirenz (EFV), stavudine (d4T) and lopinavir-ritonavir (LPVr)
and again, following rapid disease progression, 18 months after diagnosis with Efavirenz and Zidovudine (AZT) plus Lamivudine (3TC). Unbroken line
with closed circles: CD4
+ T-cell counts. Unbroken line with closed diamonds: Plasma viral loads. Broken line with closed circles: CD8
+ T-cell counts.
Blue arrow: negative HIV-1 antibody test. Red arrow: positive HIV-1 antibody test. Black arrows: Proctitis (1) / Shigellosis (2).
doi:10.1371/journal.pone.0002747.g003
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German study collective, further underscoring the fact that
resistance conferred by the CCR5 D32/D32 genotype is strong
but not complete. Transmission via contaminated blood products
in hemophiliacs [23,26] or by heterosexual contact [21] have been
reported twice and once, respectively. In the majority of these
cases [17–20,22,24,25], and also in patient #12, transmission was
through homosexual contact. However, this may well be due to
the fact that this risk group is overrepresented in the cohorts
studied so far.
Patient #12 has been under continuous observation since
seroconversion and extensive clinical information is available.
Under antiretroviral treatment, which was initiated twice in this
individual, disease progression was satisfactorily controlled.
However, a therapy-free period of 10 months revealed that the
natural disease course in this patient would have been devastating.
The apparently paradoxical association of the supposedly
protective D32/D32 genotype with unusually rapid deterioration
of immune status has been observed previously [22,26] and implies
that this genotype predisposes for rather pathogenic HIV variants;
indeed, proviral DNA and viral RNA sequence analysis indicated
CXCR4 tropism of the virus isolated from patient #12
(Kuecherer et al., separate manuscript in preparation). Exclusive
CXCR4 tropism has been described in most [23,24,26,42], but
not all [19,20] of the cases where the viral strain could be isolated.
Presence of CXCR4-tropic HIV-1 strains has been associated with
accelerated disease progression during antiretroviral therapy [43]
as well as in natural disease studies [44–46].
Our findings included, 17% (i.e., 2 out of 12) of the known HIV-
infected CCR5 D32 homozygotes are of German origin and have
obtained infection in Germany. A common transmission chain
seems rather unlikely to us, given the different geographical
residences of the patients [Hannover (Patient#5, [21]), Berlin
(Patient #12, this report)], as well as the different transmission
routes involved [i.e. heterosexually [21], homosexually (this
report)]. Neither we nor other German investigators [21,39] have
found a higher D32 allele frequency than that reported for most
Western and Central European countries [1]. Far from being
conclusive, our results might therefore indicate an enhanced
circulation of CXCR4–tropic viral strains in this geographical
region. With regard to the recent introduction of CCR5
antagonists as antiretroviral agents, this would be of paramount
interest to the clinician.
Materials and Methods
Study population
The details of the study group, which comprised 737 HIV-1-
positive adults and 463 seronegative controls, are provided in
Table 2. Seropositive individuals are either enrolled in the German
HIV-1 Seroconverter Study (n=648) or were recruited prospectively in
a private medical clinic (Jessen-Praxis, Berlin, Germany) (n=89);
written and informed consent has been obtained from all
individuals.
The German HIV-1 Seroconverter Study, representing the German
component of the CASCADE collaboration (Concerted Action on
Seroconversion to AIDS and Death in Europe) [27–29], is a
nationwide trial initiated by the Robert Koch-Institute, Berlin, in
1997. The study cohort has been described in considerable detail
elsewhere [30–32]. Briefly, HIV-1 patients with either a document-
ed HIV-antibody seroconversion (maximum time interval between
last negative and first positive HIV-1 antibody test: 3 years) or
documented ongoing seroconversion (i.e., HIV-RNA, antigen or
antibody detection with an indeterminate immunoblot followed by
completion of seroconversion) were recruited by the primary care
physicians or clinical centers listed at the end of the manuscript.
Documentation is subject to yearly follow-up and includes
demographic and clinical information as well as CD4
+ T-cell
values, viral loads and antiretroviral therapy status. To examine the
influence of host genetics on HIV-1 infection, genomic DNA of
consenting patients has been prepared from peripheral blood
specimens. 648 of the DNA samples were available for CCR5D32
genotype assessment. The median age in this patient group was 39
years (IR, 35–43 years) and 91% of the study participants were
male. The four largest transmission groups are men having sex with
men (MSM, 80%), heterosexuals (12%), patients from high-
prevalence countries (HPL, 3%), and i.v. drug users (IVDA, 3%).
For the purpose of this and other studies on the influence of host
genetic variation on susceptibility and progression of HIV-1
disease, we have been recruiting additional seroprevalents (i.e., the
duration of infection is unknown) and seroconverters not
participating in the German Seroconverter Study in a private
German clinic since 2004, 89 of whom were genotyped for
presence of the CCR5D32 deletion [33]. The median age in this
collective is 37 years (IR, 33–40) and most (96%) of the study
participants are European-Caucasian MSM. Demographic, labo-
ratory and clinical data, as well as the current therapy status, are
documented during the routine clinical visits (for the majority of
participants, 2 – 4 times / year), and are considered retrospectively
as well as prospectively. For genotyping, DNA was isolated from
EDTA whole blood samples for all study participants.
The HIV-negative control collective consisted of 428 anon-
ymized seronegative Caucasian blood donors, and 35 healthy,
unrelated volunteers. All investigations have been conducted
according to the principles expressed in the declaration of
Helsinki; written approval has been granted from the Charite ´-
Universita ¨tsmedizin Berlin Ethical Board for all studied subjects.
For disease progression studies, only those CD4
+ T cell and viral
load values gathered before the start of any antiretroviral
Table 2. Demographic characteristics of HIV positive and HIV
negative studied subjects
HIV-positive HIV-negative
Age
1 39 (34–43) 38 (33–43)
number (%)
Ethnicity
Caucasian 711 (96.5) 428 (92.4)
African 26 (3.5) 35 (7.6)
Gender
Male 674 (91.5) 434 (93.7)
Female 63 (8.5) 29 (6.3)
Risk Group n. d.
MSM 599 (81.3)
Heterosexual 79 (10.7)
IVDA 22 (3.0)
HPL 21 (2.8)
other
2 16 (1.8)
Total 737 (100.0) 463 (100.0)
1Age median (IR, interquantile range) in years.
2Of these, n=2 individuals were occupationally exposed to HIV; risk group is
unknown for n=14 individuals.
doi:10.1371/journal.pone.0002747.t002
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effects. Disease outcome was defined either by viral setpoint (data
available for 332 seroconverters, see Statistical Methods for
definition) or, in survival analysis of 506 seroconverters, by
analyzing the time from seroconversion to a CD4
+ T cell count
below 200 ml
21.
CCR5D32 genotype assessment
CCR5D32 genotyping was performed by polymerase chain
reaction (PCR) and subsequent gel electrophoresis. The reaction
mix of 25 ml contained MgCl2 at a concentration of 1.5 mM
(Qiagen,Hilden,Germany),dNTPsat200mM(Rapidozym,Berlin,
Germany), 0.5 U HotStar Taq DNA polymerase (Qiagen, Hilden,
Germany) and 5–20 ng DNA. Primers (forward, 59-CTTCAT-
CATCCTCCTGACAATCG-39; reverse, 59-GACCAGCCC-
CAAGTTGACTATC-39; TibMolbiol, Berlin, Germany) were
used at 0.5 mM each and have been previously described [34]. An
initial denaturation step of 95uC for 15 min was followed by 40
amplification cycles [94uC, 30 s; 58uC, 30 s; 72uC, 45 s] and final
extension at 72uC for 2 min. PCR amplicons of either 262 bp
(CCR5D32 wildtype) or 230 bp length (CCR5D32 deletion) were
visualized in a 3% ethidium bromide-stained agarose gel.
Heterozygous samples yielded both a 262 bp and a 230 bp band.
For the HIV-infected D32/D32 homozygous patient, presence of
the deletion was verified by molecular sequencing and by testing
DNA from a second blood sample collected on a separate occasion;
furthermore, confirmatory PCR using a different primer set [35]
was performed under the reaction conditions described above.
Homozygous wildtype, homozygous mutant, and negative control
samples were included in each reaction.
Statistical methods
CCR5D32 genotype frequencies between seropositive and
seronegative individuals were compared using the x2 test; if
expected frequencies were below 5, the exact version of the x2 test
was applied. Viral setpoints were defined as the median log10-
transformed copies of viral RNA measured in plasma between 100
days and 2 years post infection [36,37]. The strength of the
association between CCR5D32 presence and disease severity was
tested by comparison of the individual viral setpoints using the
nonparametric Mann-Whitney test. For survival analysis, the
Kaplan Meier method was applied, with the study endpoint
defined as a CD4
+ T-cell count of ,200 cells ml
21. Differences
between genotypes were tested by the log-rank test. We used
SPSS14.01 for data management and statistical analyses, and
PRISM 4 for figures.
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